Status:
COMPLETED
Retapamulin as a Decolonizing Agent for MRSA
Lead Sponsor:
NYU Langone Health
Conditions:
MRSA
Eligibility:
All Genders
9-17 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy of retapamulin to reduce carriage of MRSA via a randomized, double-blind, placebo-controlled clinical study testing retapamulin among patients ...
Eligibility Criteria
Inclusion
- Admission to the general pediatric floor and pediatric intensive care units at NYU Langone Medical Center or visit to study team members at ODA clinic (Park Ave locations) in Williamsburg Brooklyn.
- Ages 9 months to 17 years
- Residing in the zip codes which reflect Orthodox Jewish neighborhoods where there is a current outbreak of this strain of MRSA.
- Nasal and/or rectal culture positive for mupirocin-resistant methicillin-resistant Staphylococcus aureus (MRSA)
Exclusion
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnant or lactating
- Unable to appropriately consent
- Open sores in either of the study sites (nares or rectum)
- Recent surgical procedure to either study site (nares or rectum)
- Concurrent use of Rifampin or Trimethoprim/Sulfamethoxazole
- Current active MRSA infection
- Immunocompromised
- Presence of endotracheal tube, tracheostomy tube or other foreign body in upper airway
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2019
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03304873
Start Date
December 1 2017
End Date
March 18 2019
Last Update
March 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016